<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00029315</url>
  </required_header>
  <id_info>
    <org_study_id>FD-R-2018-01</org_study_id>
    <secondary_id>FD-R-002018-01</secondary_id>
    <nct_id>NCT00029315</nct_id>
  </id_info>
  <brief_title>Intraventricular Rt-PA in Patients With Intraventricular Hemorrhage</brief_title>
  <official_title>Intraventricular Rt-PA Pharmacokinetic and Pharmacodynamic Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      This is a study to evaluate how recombinant tissue plasminogen activator (rt-PA) is utilized&#xD;
      in patients with intraventricular hemorrhage (IVH). rt-PA is a drug that has been shown to&#xD;
      dissolve blood, and may allow intraventricular catheters to be more effective for a longer&#xD;
      period of time.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IVH occurs in about 40 percent of intracerebral hemorrhage cases and 15 percent of aneurysmal&#xD;
      subarachnoid hemorrhage cases. Evidence supports a strong contribution of IVH to morbidity&#xD;
      and mortality after cerebral hemorrhage. External ventricular drainage (EVD) is required&#xD;
      clinical management; however, EVD via intraventricular catheter alone fails to prevent much&#xD;
      of the morbidity and mortality of IVH. This study seeks to demonstrate the safety and&#xD;
      efficacy of intraventricular thrombolysis, using rt-PA, as a method of removing this blood&#xD;
      and altering morbidity and mortality. Patients will receive intraventricular injections of&#xD;
      rt-PA or placebo every 12 hours. They will be followed prospectively with daily head CT scans&#xD;
      during the acute-treatment phase and again between Days 28 and 32.&#xD;
&#xD;
      Completion date provided represents the completion date of the grant per OOPD records&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <completion_date>September 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cerebral Hemorrhage</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Tissue Plasminogen Activator (rt-PA)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Intraventricular hemorrhage (IVH) confirmed by CT scan&#xD;
&#xD;
          -  More than 12 hours post bleed&#xD;
&#xD;
          -  Hematoma size stable by CT scan&#xD;
&#xD;
          -  Post-IVH catheter CT scan&#xD;
&#xD;
          -  Able to begin study within 24 hours of bleed&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Infratentorial bleed&#xD;
&#xD;
          -  Supratentorial bleed greater than 30 cc&#xD;
&#xD;
          -  Unclipped aneurysm suspected&#xD;
&#xD;
          -  Arteriovenous malformation suspected&#xD;
&#xD;
          -  Any severe, complicating illness (e.g., AIDS or DNR)&#xD;
&#xD;
          -  Cardiovascular parameters that could confound study (e.g., myocardial infarction,&#xD;
             pulmonary emboli, systemic fibrinolysis)&#xD;
&#xD;
          -  Active internal bleeding&#xD;
&#xD;
          -  Requirement for heparin doses greater than 10,000 U/day&#xD;
&#xD;
          -  Concurrent coumadin&#xD;
&#xD;
          -  Known allergy to rt-PA&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2001</verification_date>
  <study_first_submitted>January 10, 2002</study_first_submitted>
  <study_first_submitted_qc>January 10, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2002</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <keyword>Intraventricular hemorrhage</keyword>
  <keyword>Subarachnoid hemorrhage</keyword>
  <keyword>Intracerebral hemorrhage</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Recombinant Proteins</keyword>
  <keyword>Anticoagulants</keyword>
  <keyword>Tissue Plasminogen Activator</keyword>
  <keyword>Pharmacology</keyword>
  <keyword>Catheters, Indwelling</keyword>
  <keyword>Cerebral Ventricles</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasminogen</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

